Fig. 2

OS estimated with the Kaplan-Meier method for non- metastatic PDAC. A.OS estimated with the Kaplan-Meier method for PDAC patients with T1-3N0M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p = 0.223; surgery alone vs. neoadjuvant radiotherapy: p = 0.027; surgery alone vs. surgery plus chemotherapy: p = 0.007;adjuvant radiotherapy vs. surgery plus chemotherapy: p = 0.023). B. OS estimated with the Kaplan-Meier method for PDAC patients with T1-3N + M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p < 0.001; surgery alone vs. neoadjuvant radiotherapy: p = 0.001; surgery alone vs. surgery plus chemotherapy: p < 0.001;adjuvant radiotherapy vs. neoadjuvant radiotherapy: p = 0.017;adjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001). C. OS estimated with the Kaplan-Meier method for PDAC patients with T4N0M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p = 0.353; surgery alone vs. neoadjuvant radiotherapy: p < 0.001; surgery alone vs. surgery plus chemotherapy: p = 0.001;adjuvant radiotherapy vs. neoadjuvant radiotherapy: p < 0.001;adjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001;neoadjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001). D. OS estimated with the Kaplan-Meier method for PDAC patients with T4N + M0 stage receiving different treatment methods (surgery alone versus (vs.) adjuvant radiotherapy: p = 0.353; surgery alone vs. neoadjuvant radiotherapy: p < 0.001; surgery alone vs. surgery plus chemotherapy: p < 0.001;adjuvant radiotherapy vs. neoadjuvant radiotherapy: p < 0.001;adjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001;neoadjuvant radiotherapy vs. surgery plus chemotherapy: p < 0.001)